Theratechnologies Inc (THTX)

$1.36

+0.03

(+2.26%)▲

Live

Performance

  • $1.31
    $1.40
    $1.36
    downward going graph

    3.68%

    Downside

    Day's Volatility :6.43%

    Upside

    2.86%

    downward going graph
  • $0.88
    $2.58
    $1.36
    downward going graph

    35.29%

    Downside

    52 Weeks Volatility :65.89%

    Upside

    47.29%

    downward going graph

Returns

PeriodTheratechnologies IncIndex (Russel 2000)
3 Months
-14.74%
0.0%
6 Months
-0.75%
0.0%
1 Year
-2.92%
0.0%
3 Years
-90.58%
-23.0%

Highlights

Market Capitalization
58.9M
Book Value
-$0.43
Earnings Per Share (EPS)
-0.04
Wall Street Target Price
18.0
Profit Margin
-3.75%
Operating Margin TTM
27.49%
Return On Assets TTM
11.76%
Return On Equity TTM
-1116.86%
Revenue TTM
84.3M
Revenue Per Share TTM
1.87
Quarterly Revenue Growth YOY
8.4%
Gross Profit TTM
56.2M
EBITDA
14.4M
Diluted Eps TTM
-0.04
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.03
EPS Estimate Next Year
0.11
EPS Estimate Current Quarter
-0.02
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Theratechnologies Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1223.53%

Current $1.36
Target $18.00

Company Financials

FY18Y/Y Change
Revenue
44.1M
↑ 32.59%
Net Income
-4.5M
↓ 68.37%
Net Profit Margin
-10.27%
↑ 32.77%
FY19Y/Y Change
Revenue
63.2M
↑ 43.49%
Net Income
-12.5M
↑ 176.21%
Net Profit Margin
-19.77%
↓ 9.5%
FY20Y/Y Change
Revenue
66.1M
↑ 4.49%
Net Income
-22.7M
↑ 81.39%
Net Profit Margin
-34.32%
↓ 14.55%
FY21Y/Y Change
Revenue
69.8M
↑ 5.71%
Net Income
-31.7M
↑ 39.96%
Net Profit Margin
-45.44%
↓ 11.12%
FY22Y/Y Change
Revenue
80.1M
↑ 14.66%
Net Income
-47.2M
↑ 48.9%
Net Profit Margin
-59.0%
↓ 13.56%
FY23Y/Y Change
Revenue
81.8M
↑ 2.13%
Net Income
-24.0M
↓ 49.28%
Net Profit Margin
-29.3%
↑ 29.7%
Q1 FY23Q/Q Change
Revenue
19.9M
↓ 7.06%
Net Income
-10.4M
↑ 31.71%
Net Profit Margin
-52.46%
↓ 15.44%
Q2 FY23Q/Q Change
Revenue
20.9M
↑ 4.76%
Net Income
-746.0K
↓ 92.86%
Net Profit Margin
-3.58%
↑ 48.88%
Q3 FY23Q/Q Change
Revenue
20.9M
↑ 0.0%
Net Income
-746.0K
↑ 0.0%
Net Profit Margin
-3.58%
↑ 0.0%
Q4 FY23Q/Q Change
Revenue
23.5M
↑ 12.45%
Net Income
-2.8M
↑ 269.3%
Net Profit Margin
-11.75%
↓ 8.17%
Q1 FY24Q/Q Change
Revenue
22.0M
↓ 6.15%
Net Income
987.0K
↓ 135.83%
Net Profit Margin
4.48%
↑ 16.23%
Q2 FY24Q/Q Change
Revenue
22.6M
↑ 2.68%
Net Income
3.1M
↑ 213.17%
Net Profit Margin
13.68%
↑ 9.2%
FY18Y/Y Change
Total Assets
111.1M
↑ 87.93%
Total Liabilities
76.1M
↑ 243.01%
FY19Y/Y Change
Total Assets
117.6M
↑ 5.77%
Total Liabilities
92.7M
↑ 21.81%
FY20Y/Y Change
Total Assets
100.1M
↓ 14.81%
Total Liabilities
96.9M
↑ 4.53%
FY21Y/Y Change
Total Assets
119.2M
↑ 19.04%
Total Liabilities
101.5M
↑ 4.68%
FY22Y/Y Change
Total Assets
93.3M
↓ 21.77%
Total Liabilities
115.8M
↑ 14.17%
FY23Y/Y Change
Total Assets
77.8M
↓ 16.61%
Total Liabilities
98.6M
↓ 14.84%
Q1 FY23Q/Q Change
Total Assets
79.2M
↓ 15.03%
Total Liabilities
111.6M
↓ 3.7%
Q2 FY23Q/Q Change
Total Assets
56.7M
↓ 28.46%
Total Liabilities
98.4M
↓ 11.8%
Q3 FY23Q/Q Change
Total Assets
56.7M
↑ 0.0%
Total Liabilities
98.4M
↑ 0.0%
Q4 FY23Q/Q Change
Total Assets
77.8M
↑ 37.19%
Total Liabilities
98.6M
↑ 0.25%
Q1 FY24Q/Q Change
Total Assets
70.2M
↓ 9.73%
Total Liabilities
93.4M
↓ 5.3%
Q2 FY24Q/Q Change
Total Assets
69.7M
↓ 0.7%
Total Liabilities
89.4M
↓ 4.3%
FY18Y/Y Change
Operating Cash Flow
-334.1K
↓ 117.55%
Investing Cash Flow
-9.9M
↓ 52.23%
Financing Cash Flow
46.8M
↑ 241.54%
FY19Y/Y Change
Operating Cash Flow
-3.4M
↑ 915.09%
Investing Cash Flow
-130.0K
↓ 98.69%
Financing Cash Flow
-6.8M
↓ 114.53%
FY20Y/Y Change
Operating Cash Flow
-13.6M
↑ 299.71%
Investing Cash Flow
4.8M
↓ 3773.85%
Financing Cash Flow
-7.2M
↑ 6.2%
FY21Y/Y Change
Operating Cash Flow
-14.5M
↑ 6.81%
Investing Cash Flow
-12.5M
↓ 360.76%
Financing Cash Flow
37.9M
↓ 623.77%
FY22Y/Y Change
Operating Cash Flow
-14.7M
↑ 1.49%
Investing Cash Flow
8.7M
↓ 169.71%
Financing Cash Flow
9.7M
↓ 74.5%
Q1 FY23Q/Q Change
Operating Cash Flow
-3.3M
↓ 59.5%
Investing Cash Flow
734.0K
↓ 77.78%
Financing Cash Flow
-162.0K
↓ 102.96%
Q2 FY23Q/Q Change
Operating Cash Flow
5.3M
↓ 259.6%
Investing Cash Flow
734.0K
↑ 0.0%
Financing Cash Flow
-7.9M
↑ 4785.19%
Q3 FY23Q/Q Change
Operating Cash Flow
5.3M
↑ 0.0%
Investing Cash Flow
558.0K
↓ 23.98%
Financing Cash Flow
-7.9M
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Theratechnologies Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Theratechnologies Inc
Theratechnologies Inc
6.83%
-0.75%
-2.92%
-90.58%
-91.2%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Theratechnologies Inc
Theratechnologies Inc
NA
NA
NA
0.03
-11.17
0.12
NA
-0.43
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Theratechnologies Inc
Theratechnologies Inc
Buy
$58.9M
-91.2%
NA
-3.75%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Theratechnologies Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 22.01M → 22.6M (in $), with an average increase of 2.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -2.75M → 3.09M (in $), with an average increase of 223.6% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 95.4%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 135.4%

Institutional Holdings

  • Nantahala Capital Management, LLC

    11.67%

  • Soleus Capital Management, L.P.

    10.44%

  • AIGH Capital Management, LLC

    8.10%

  • Morgan Stanley - Brokerage Accounts

    4.90%

  • Advisor Group Holdings, Inc.

    0.32%

  • Cyndeo Wealth Partners LLC

    0.23%

Company Information

theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.

Organization
Theratechnologies Inc
Employees
103
CEO
Mr. Paul Lévesque
Industry
Health Technology

Discover More

FAQs